MONTREAL, Nov. 12, 2024 (GLOBE NEWSWIRE) -- MUHC health care staff and supporters took to the stage at Beanfield Theatre…
Fully enrolled the Phase 2/3 trial of lead asset CTX-009 (DLL4 and VEGF-A bispecific antibody) in patients with biliary tract…
GERMANTOWN, Md., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on…
ALLENDALE, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Acuitive Technologies, Inc. today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market CITREPORE, a…
On track to report interim data in six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in 4Q 2024Expect…
TORONTO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device…
BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of…
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services,…
Provides 22% Overall Improvement in Detecting Challenging and Aggressive Cancer Subtypes and Enables Clinicians to Incorporate a Prior Exam into…